Form 4: Dare Bioscience CEO Granted 172,000 Stock Options

Dare Bioscience CEO Sabrina Martucci Johnson acquired 172,000 employee stock options at an exercise price of $1.81, vesting over 48 months.

Summary

• Sabrina Martucci Johnson, CEO and Director of Dare Bioscience, Inc. (DARE), acquired 172,000 employee stock options.
• The options have an exercise price of $1.81 per share.
• The transaction date for the option grant was January 30, 2026.
• These options vest and become exercisable in 48 equal monthly installments, commencing on the one-month anniversary of the grant date, subject to continuous service.
• The expiration date for these options is January 30, 2036.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, primarily due to the alignment of management and shareholder interests through long-term equity incentives, though it is a routine compensation matter.

Positives

• The grant of stock options to the CEO aligns her long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• The use of a Rule 10b5-1 plan demonstrates a commitment to transparent and pre-planned insider transactions, reducing potential concerns about opportunistic trading.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, as new shares would be issued.

Future Outlook

The grant of long-term stock options to the CEO suggests an expectation of continued service and a focus on long-term value creation for Dare Bioscience, Inc.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract and retain key talent while aligning management incentives with shareholder returns. StockSavvy.ai notes that the exercise price of $1.81 reflects the stock price at the time of grant, a standard practice.

Comparison to Industry Standards

• The grant of 172,000 stock options to a CEO of a biotechnology company like Dare Bioscience is within the typical range for executive compensation packages, comparable to similar-sized firms in the sector.
• The 48-month vesting schedule is a standard practice, often seen in companies like Moderna or BioNTech for executive equity awards, promoting long-term commitment.
• The use of a Rule 10b5-1 plan is a best practice in corporate governance, widely adopted by executives across industries to manage stock transactions compliantly.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of CEO's interests with long-term company performance.
• Employees: The CEO's long-term incentive structure may signal stability and commitment, potentially impacting employee morale and retention.

Next Steps

• The stock options will vest in 48 equal monthly installments, commencing one month after the grant date of January 30, 2026, subject to the CEO's continuous service.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options as part of executive compensation. While it signals management's long-term commitment, it does not present new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it's a neutral, expected event.

Keywords

Dare Bioscience, DARE, Sabrina Martucci Johnson, Stock Options, Insider Transaction, Form 4, Executive Compensation, Rule 10b5-1